Steven Seedhouse
Stock Analyst at Raymond James
(3.52)
# 899
Out of 5,008 analysts
178
Total ratings
45.93%
Success rate
6.09%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETNB 89bio | Downgrades: Market Perform | n/a | $14.87 | - | 11 | Sep 19, 2025 | |
| ATXS Astria Therapeutics | Reiterates: Overweight | $49 | $7.69 | +537.19% | 2 | Sep 17, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $34.46 | +82.82% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $43.70 | +236.38% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $72.53 | +13.06% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $7.22 | +38.50% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $23.25 | +20.43% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.51 | +562.25% | 14 | Apr 29, 2025 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Overweight | $20 | $7.02 | +184.90% | 1 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $32.28 | +222.18% | 20 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $90 → $22 | $2.17 | +913.82% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $2.36 | +493.22% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $113.58 | -18.12% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $30.94 | +119.78% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $24.36 | +335.14% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $5.20 | +188.46% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $12.65 | +342.69% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.76 | +2,191.48% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $20.54 | +177.51% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $4.17 | +427.58% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $3.80 | +347.37% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.18 | +1,000.63% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $57.55 | -33.97% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $46.18 | +53.75% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $2.41 | +107.47% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $30.25 | +25.62% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $21.01 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.61 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $11.60 | +2,227.59% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $154.05 | - | 2 | Apr 23, 2020 |
89bio
Sep 19, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $14.87
Upside: -
Astria Therapeutics
Sep 17, 2025
Reiterates: Overweight
Price Target: $49
Current: $7.69
Upside: +537.19%
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $34.46
Upside: +82.82%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $43.70
Upside: +236.38%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $72.53
Upside: +13.06%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $7.22
Upside: +38.50%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $23.25
Upside: +20.43%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.51
Upside: +562.25%
BioCryst Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $20
Current: $7.02
Upside: +184.90%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $32.28
Upside: +222.18%
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $2.17
Upside: +913.82%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.36
Upside: +493.22%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $113.58
Upside: -18.12%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $30.94
Upside: +119.78%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $24.36
Upside: +335.14%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $5.20
Upside: +188.46%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $12.65
Upside: +342.69%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.76
Upside: +2,191.48%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $20.54
Upside: +177.51%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $4.17
Upside: +427.58%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $3.80
Upside: +347.37%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.18
Upside: +1,000.63%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $57.55
Upside: -33.97%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $46.18
Upside: +53.75%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $2.41
Upside: +107.47%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $30.25
Upside: +25.62%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $21.01
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.61
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $11.60
Upside: +2,227.59%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $154.05
Upside: -